Aegis Capital Starts Navidea Biopharmaceuticals (NAVB) at Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Burrill Starts Navidea Biopharmaceuticals (NAVB) at Market Outperform
January 22, 2013 7:21 AM ESTBurrill initiates coverage on Navidea Biopharmaceuticals (NYSE: NAVB) with a Market Outperform. PT $5.00.
The firm comments, "Navidea is currently seeking regulatory approval of Lymphoseek, a precision radiopharmaceutical agent used for intraoperative lymphatic mapping, and in our opinion, addresses a $300 MM worldwide market. In... More
